ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.061,23
0,32%
S&P 500
5.917,11
0,00%
Dow Jones
43.408,47
0,32%
Euro vs US Dollar
1,05206
-0,24%
Bitcoin
97.773,10
3,62%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Adagene Inc (ADAG) Börsenkurse

Adagene Inc

Adagene Inc (ADAG)

NASDAQ
2,09
-0,13
(-5,86%)
Geschlossen 21 November 10:00PM
Verzögert um 15 Minuten
2,09
0,00
( 0,00% )
Vor Marktöffnung: 10:40AM
Verzögert um 15 Minuten

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
2,09
Gebot
2,01
Fragen
2,80
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
92,204M
Handelsende
2,09
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
44.116.671
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-4,87
Gewinn pro Aktie (EPS)
-0,43
Erlöse
21,59M
Nettogewinn
-18,95M

Über Adagene Inc

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reacti... Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Grand Cayman, Cym
Gegründet
-
Adagene Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ADAG. The last closing price for Adagene was US$2,09. Over the last year, Adagene shares have traded in a share price range of US$ 0,00 to US$ 0,00.

Adagene currently has 44.116.671 shares in issue. The market capitalisation of Adagene is US$92,20 million. Adagene has a price to earnings ratio (PE ratio) of -4.87.

ADAG Neueste Nachrichten

Weitere Nachrichten

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

07 November 2024
Edgar (US Regulatory)

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

07 November 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

07 November 2024
Edgar (US Regulatory)

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc

- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4...

07 November 2024
GlobeNewswire Inc.

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies...

09 Oktober 2024
GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

24 September 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

16 September 2024
Edgar (US Regulatory)

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC

- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg...

16 September 2024
GlobeNewswire Inc.

Adagene to Participate in Investor Conferences in September

SAN DIEGO and SUZHOU, China, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and...

29 August 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

25 Juli 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
WORXSCWorx Corporation
US$ 1,98
(102,04%)
16,34M
AKTSAkoustis Technologies Inc
US$ 0,1321
(51,66%)
57,77M
PETWag Group Company
US$ 0,303
(44,22%)
18,31M
ESGROEnstar Group Ltd
US$ 28,00
(40,92%)
28
CCECCapital Clean Energy Carriers Corporation
US$ 24,99
(34,72%)
11
WSBFWaterstone Financial Inc
US$ 9,00
(-40,98%)
4
TRSTriMas Corporation
US$ 15,62
(-40,79%)
3
BCAXBicara Therapeutics Inc
US$ 11,00
(-40,15%)
212
PYXSPyxis Oncology Inc
US$ 2,43
(-36,39%)
209,56k
XNCRXencor Inc
US$ 15,11
(-36,30%)
2
AKTSAkoustis Technologies Inc
US$ 0,1321
(51,66%)
57,77M
PETWag Group Company
US$ 0,303
(44,22%)
18,31M
WORXSCWorx Corporation
US$ 1,98
(102,04%)
16,34M
XTKGX3 Holdings Company Ltd
US$ 0,0775
(-13,89%)
10,83M
CRKNCrown Electrokinetics Corporation
US$ 0,9853
(25,41%)
5,59M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
ADAG
Adagene
LSE
0EW3
Isxis Investment Public
USOTC
SLFPF
Abrdn (PK)
USOTC
AECLY
AE and CI (PK)
USOTC
ARRJF
ARJO AB (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten